Altered growth hormone secretion during oral contraception

Area of Science:

• Endocrinology
• Reproductive Medicine
• Pharmacology

Background:

• Growth hormone (GH) plays a crucial role in metabolism and body composition.
• Combined oral contraceptives (COCs) contain synthetic sex steroids that can influence endocrine function.
• Previous research suggests potential interactions between sex steroids and GH secretion.

Purpose of the Study:

• To investigate the effect of monophasic combined contraceptives on serum growth hormone (GH) profiles in young healthy women.
• To quantify changes in GH secretion patterns, including peak amplitude, area, and frequency, during COC treatment.

Main Methods:

• Serum GH levels were measured over a 24-hour period in 9 healthy women.
• Measurements were taken both before and during treatment with a monophasic combined contraceptive.
• Analysis focused on changes in GH peak characteristics and interpeak intervals.

Main Results:

• Treatment with combined contraceptives resulted in a significant alteration of GH secretion patterns.
• GH secretion shifted towards more frequent, smaller peaks.
• Mean peak amplitude decreased from 11.2 to 7.3 mU/l, mean peak area from 24.1 to 14.1 mU/l, and mean interpeak interval from 4.3 to 3.0 hours.

Conclusions:

• Monophasic combined contraceptives induce a distinct change in the pulsatile secretion of GH in young women.
• The observed alterations in GH secretion, characterized by reduced amplitude and increased frequency, may contribute to the metabolic effects associated with oral contraceptive use.
• These findings highlight a potential mechanism linking sex steroid administration to metabolic changes via modulation of GH dynamics.